Eyenovia to Present at the 22nd Annual H.C. Wainwright Global Investment Conference
09 Settembre 2020 - 2:30PM
Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic
biopharmaceutical company developing a pipeline of microdose array
print (MAP™) therapeutics, today announced that Dr. Sean Ianchulev,
Eyenovia’s Chief Executive Officer and Chief Medical Officer and
John Gandolfo, Eyenovia’s Chief Financial Officer, are scheduled to
present at the 22nd Annual H.C. Wainwright Global Investment
Conference being held virtually on September 14-16, 2020.
Details of the presentation are below:
Event: 22nd Annual H.C.
Wainwright Global Investment ConferenceDate:
Tuesday, September 15, 2020Presentation Time:
2:30-2:50 PM ET
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is a clinical
stage ophthalmic biopharmaceutical company developing a pipeline of
microdose array print (MAP™) therapeutics. Eyenovia’s pipeline is
currently focused on the late-stage development of microdosed
medications for presbyopia, myopia progression and mydriasis. For
more Information, please visit www.eyenovia.com.
Company Contact:Eyenovia,
Inc.John GandolfoChief Financial Officerjgandolfo@eyenovia.com
Investor Contact:The Ruth
GroupCarol RuthPhone: 646-536-7004cruth@theruthgroup.com
Grafico Azioni Eyenovia (NASDAQ:EYEN)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Eyenovia (NASDAQ:EYEN)
Storico
Da Mag 2023 a Mag 2024
